BioXcel Therapeutics - BTAI Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued twelve-month price objectives for BioXcel Therapeutics' shares. Their BTAI share price forecasts range from $22.00 to $80.00. On average, they expect the company's stock price to reach $53.33 in the next year. This suggests a possible upside of 185.8% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.

BioXcel Therapeutics' stock was trading at $21.48 at the beginning of 2023. Since then, BTAI stock has decreased by 13.1% and is now trading at $18.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our BTAI earnings forecast.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Thursday, March, 9th. The company reported ($1.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.49) by $0.46. The company earned $0.24 million during the quarter, compared to analysts' expectations of $1.08 million. During the same quarter in the previous year, the firm posted ($0.93) EPS.

ETFs with the largest weight of BioXcel Therapeutics (NASDAQ:BTAI) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), WisdomTree Artificial Intelligence and Innovation Fund (WTAI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BTAI stock can currently be purchased for approximately $18.66.

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $541.33 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($5.91) on an earnings per share basis.

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.